These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

991 related items for PubMed ID: 26681527

  • 61. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T.
    Hum Vaccin Immunother; 2017 Oct 03; 13(10):2247-2259. PubMed ID: 28825875
    [Abstract] [Full Text] [Related]

  • 62. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
    van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, Gong Y, Huang J, Papavassilis C, Fox T.
    J Am Acad Dermatol; 2016 Jul 03; 75(1):83-98.e4. PubMed ID: 27180926
    [Abstract] [Full Text] [Related]

  • 63. A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.
    Campa M, Menter A.
    Expert Opin Investig Drugs; 2016 Nov 03; 25(11):1337-1344. PubMed ID: 27687859
    [Abstract] [Full Text] [Related]

  • 64. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
    Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB.
    J Eur Acad Dermatol Venereol; 2019 Feb 03; 33(2):355-366. PubMed ID: 30289198
    [Abstract] [Full Text] [Related]

  • 65. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T, Schäkel K.
    J Dermatolog Treat; 2019 May 03; 30(3):216-220. PubMed ID: 30051725
    [Abstract] [Full Text] [Related]

  • 66. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A.
    Cutis; 2009 Oct 03; 84(4 Suppl):14-24. PubMed ID: 19916298
    [Abstract] [Full Text] [Related]

  • 67. The Role of Biologic Therapies in Dermatology.
    Fathi R, Armstrong AW.
    Med Clin North Am; 2015 Nov 03; 99(6):1183-94. PubMed ID: 26476247
    [Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70. Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies.
    Lasagni C, Bigi L, Conti A, Pellacani G.
    J Dermatolog Treat; 2018 Nov 03; 29(sup2):5-8. PubMed ID: 30403898
    [Abstract] [Full Text] [Related]

  • 71. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C, Plotnikova N, Au SC, Sorensen EP, Gottlieb A.
    J Drugs Dermatol; 2015 Aug 03; 14(8):846-52. PubMed ID: 26267729
    [Abstract] [Full Text] [Related]

  • 72. Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study.
    Wu NL, Hsu CJ, Sun FJ, Tsai TF.
    J Dermatol; 2017 Oct 03; 44(10):1129-1137. PubMed ID: 28493369
    [Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
    Körber A, Papavassilis C, Bhosekar V, Reinhardt M.
    Drugs Aging; 2018 Feb 03; 35(2):135-144. PubMed ID: 29404966
    [Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB.
    Br J Dermatol; 2013 Feb 03; 168(2):412-21. PubMed ID: 23106107
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 50.